Orgalutran (Ganirelix)

Ganirelix, the active ingredient in Orgalutran, is a GnRH antagonist presented as a 0.25 mg injection solution for subcutaneous use. It prevents premature luteinising hormone surges during controlled ovarian stimulation in assisted reproductive technology cycles.

GNH USA supplies Orgalutran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orgalutran is a GnRH antagonist that acts within the reproductive hormone pathway to control ovulation timing during assisted reproduction. - Controlled ovarian stimulation (COS): prevents premature LH surge, allowing scheduled oocyte retrieval. - In vitro fertilisation (IVF) cycles: supports synchronized follicular development for optimal embryo collection. - Intracytoplasmic sperm injection (ICSI) cycles: aids timing of egg maturation to improve procedural success.

Adverse reactions to Ganirelix are generally mild and reversible.

Common Side Effects: - Injection site erythema: redness at the injection site. - Injection site pain: mild to moderate discomfort. - Headache: transient headache. - Nausea: occasional mild nausea. - Fatigue: feeling of tiredness. - Vaginal spotting: light spotting after administration.

Serious or Rare Side Effects: - Allergic reaction: rash, pruritus, or anaphylaxis. - Severe abdominal pain: persistent or worsening abdominal discomfort. - Ovarian hyperstimulation syndrome (OHSS): signs of fluid shift or rapid weight gain. - Thromboembolic events: rare clot formation. - Hypersensitivity: systemic allergic response requiring medical attention.

When using Ganirelix, clinicians should assess patient history and monitor response throughout treatment. - Pregnancy testing: confirm absence of pregnancy before initiating therapy. - Ovarian reserve assessment: evaluate baseline ovarian function. - Monitoring LH levels: ensure adequate suppression during stimulation. - OHSS risk evaluation: identify patients at high risk for ovarian hyperstimulation syndrome. - Drug‑interaction review: check concomitant medications that may affect gonadotropin response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ganirelix may interact with other agents that influence the hypothalamic‑pituitary‑gonadal axis.

Major Interactions (Avoid): - GnRH agonists: concurrent use can counteract antagonist effect. - Hormonal contraceptives: may alter suppression dynamics.

Moderate Interactions (Monitor Closely): - Gonadotropins (FSH, hMG): dose adjustments may be needed. - Steroids used in IVF protocols: monitor for additive effects on hormone levels. - Anticoagulants: observe for any changes in bleeding risk during oocyte retrieval. - CYP‑mediated drugs: although Ganirelix is not extensively metabolised by CYP enzymes, observe for unexpected pharmacodynamic changes. - Herbal supplements: assess for any impact on ovarian response.